Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817362 | 1.00 | FOLH1 (0.36) | FOLH1MEN1GAAKMT2AKDM4C | |
| SCHEMBL1814083 | 0.90 | FOLH1 (0.41) | FOLH1MEN1GAAKMT2AADRA1A | |
| SCHEMBL1814511 | 0.90 | FOLH1 (0.41) | FOLH1MEN1GAAKMT2AADRA1A | |
| SCHEMBL1812967 | 0.90 | FOLH1 (0.41) | FOLH1MEN1GAAKMT2AADRA1A | |
| SCHEMBL1815224 | 0.90 | FOLH1 (0.41) | FOLH1MEN1GAAKMT2AADRA1A | |
| SCHEMBL1815319 | 0.89 | FOLH1 (0.35) | FOLH1MEN1GAAKMT2AKDM4C | |
| SCHEMBL1817347 | 0.89 | FOLH1 (0.35) | FOLH1MEN1GAAKMT2AKDM4C | |
| SCHEMBL1812960 | 0.88 | FOLH1 (0.37) | FOLH1MEN1GAAKMT2AKDM4C | |
| SCHEMBL1818208 | 0.88 | FOLH1 (0.37) | FOLH1MEN1GAAKMT2AKDM4C | |
| SCHEMBL1814427 | 0.88 | FOLH1 (0.34) | FOLH1MEN1GAAKMT2AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, CHRNG | FOLH1 305/4885MEN1 2810/4885GAA 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.